| Genscript Biotech | |
|---|---|
| Another Biotech Analyst Is Ditching Wall Street for a CFO Role | June 19, 2019 |
| Genscript Biotech Halted Pending Inside Information Announcement | September 26, 2018 |
| J&J to Build Blood-Cancer Push With Controversial China Biotech | December 2, 2018 |
| Genscript Surges After Therapy Gets PRIME Designation From EMA | April 7, 2019 |
| China Drugmakers Fall as Premier Vows to Lower Prices in 2019 | January 21, 2019 |
| Genscript Biotech Shares Decline 16% to Lowest in Six Weeks | September 26, 2018 |
| Genscript Biotech Denies All Allegations in Flaming Report | September 27, 2018 |
| Legend-J&J CAR-T Has Durable Responses; Comparison Has Caveats | November 1, 2018 |
| Genscript Biotech Denies Flaming Allegations in Second Report | October 2, 2018 |
| [Delayed] China Healthcare Sector: Factoring new risks and highlighting opportunitie | November 15, 2018 |
| Genscript Biotech Rebounds After Denying Allegations in Report | September 27, 2018 |
| Genscript Entitles to $55M Milestone Payment From Janssen | July 28, 2019 |
| Genscript Biotech Volume Jumps More Than Five Times Average | September 26, 2018 |
| Genscript Biotech Shares Advance 15% to Highest in Nine Months | April 10, 2019 |
| Genscript Biotech Reports to H.K. SFC After Flaming Allegations | October 12, 2018 |
| Genscript Bio Advances After Saying Milestone Reached in Trial | December 17, 2018 |
| Merck KGaA Announces MoU Signing With Chinese Biotech GenScript | March 19, 2019 |
| Genscript Biotech Jumps as Unit Entitled to Milestone Payment | July 28, 2019 |
| Genscript Biotech Stock Rises 9.3% Climbing the Most in 2019 | April 7, 2019 |
| Genscript Biotech Buys Back 1.84M Shares for HK$26.9M Oct. 3 | October 3, 2018 |
AnalystSolutions respects your privacy and will never share your information with others. You can remove yourself from any distribution with one click.
AnalystSolutions respects your privacy and will never share your information with others. You can remove yourself from any distribution with one click.
We offer free full versions of our content for evaluation purposes (valued at over $700) to professionals holding the following roles:
You will receive:
To ensure a quick verification of your role above (usually within one business day), please provide the email address issued by your organization.
You will be directed to the FREE SAMPLE EDITION of our GAMMA PI™ Equity Research Analyst Self-Assessment. Please provide a valid email address to receive your results (your email address remains confidential within AnalystSolutions).
Please answer these questions to help James Valentine prepare for your call (he will keep your responses confidential)
You will be directed to our 20-question quiz to determine if you possess the skills of a seasoned equity research analyst. Please provide a valid email address to receive your results (your email address remains confidential within AnalystSolutions):
We will attempt to reply to you within one business day based upon the responses to our questions below.